胸腺肽α1对慢性乙型肝炎CD4+CD25+CD127dim/-调节性T淋巴细胞功能的影响

李彧; 田颖; 杨晓梅; 曹宁家; 李竹; 张鸿; 张先娇

doi:10.3969/j.issn.1001-5256.2018.05.017

胸腺肽α1对慢性乙型肝炎CD4+CD25+CD127dim/-调节性T淋巴细胞功能的影响

DOI: 10.3969/j.issn.1001-5256.2018.05.017

1. 陕西省人民医院感染性疾病科
2. 陕西省中医医院妇科
3. 陕西省人民医院妇科
4. 陕西省人民医院科研处

基金项目:

陕西省自然科学基金(2013JQ4044)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2189
- HTML全文浏览量: 46
- PDF下载量: 392
- 被引次数: 0
出版历程
- 收稿日期: 2018-01-29
- 出版日期: 2018-05-20

Effect of thymosin α1 on the function of CD4+CD25+CD127dim/- regulatory T cells in chronic hepatitis B patients

Department of Infectious Diseases, Shaanxi Provincial People's Hospital

Research funding:

摘要

摘要: 目的观察胸腺肽α1对慢性乙型肝炎CD4+CD25+CD127dim/-调节性T淋巴细胞（Treg）功能的影响。方法选取2016年12月-2017年7月陕西省人民医院感染性疾病科收治的慢性乙型肝炎患者67例,其中38例接受恩替卡韦抗病毒治疗（对照组）,29例接受恩替卡韦联合注射用胸腺肽α1治疗（治疗组）,分别于治疗前后分离外周血单个核细胞,流式细胞术检测CD4+CD25+CD127dim/-Treg水平,纯化CD4+CD25+CD127dim/-Treg,与自体CD4+CD25-T淋巴细胞共培养,CCK-8法检测细胞增殖,ELISA法检测细胞因子分泌水平。计量资料2组间比较采用t检验,计数资料组间比较采用χ2检验。结果对照组、治疗组患者经治12周CD4+CD25+CD127dim/-Treg均较基线水平明显下降,差异均有统计学意...
- 肝炎,乙型,慢性 /
- T淋巴细胞,调节性 /
- 胸腺素
Abstract: Objective To investigate the effect of thymosin α1 therapy on the function of CD4+CD25+CD127dim/-regulatory T ( Treg) cells in chronic hepatitis B ( CHB) patients. Methods A total of 67 CHB patients who were admitted to Department of Infectious Diseases in Shaanxi Provincial People's Hospital from December 2016 to July 2017 were enrolled, among whom 38 patients received entecavir antiviral therapy ( control group) and 29 received entecavir combined with thymosin α1 for injection ( treatment group) . Peripheral blood mononucleated cells were isolated before and after treatment, and flow cytometry was used to measure the percentage of CD4+CD25+CD127dim/-Treg cells. CD4+CD25+CD127dim/-Treg cells were purified and co-cultured with autologous CD4+CD25-T cells. CCK-8 assay was used to measure cell proliferation, and ELISA was used to measure the levels of cytokines. The t-test was used for comparison of related indices between the two groups, the chi-square test was used for comparison of categorical data. Results In the control group, the percentage of CD4+CD25+CD127dim/-Treg cells was significantly reduced from 12. 32% ± 1. 22% at baseline to 8. 85% ± 2. 18% after 12 weeks of treatment ( t = 4. 579, P = 0. 0005) , while in the treatment group, this value was significantly reduced from 13. 71% ± 2. 32% at baseline to 9.26% ± 2. 30% after 12 weeks of treatment ( t = 4. 803, P = 0. 0003) . The measurement of cytokines was performed for 17 patients in the control group and 21 in the treatment group. After 12 weeks of treatment, the control group showed no significant changes in cell proliferation and levels of cytokines in the co-culture system of Treg and CD4+CD25-T cells; the treatment group had a significant increase in cell count in the co-culture system [ ( 3. 66 ± 0. 95) × 106 vs ( 2. 07 ± 0. 51) × 106, t = 5. 709, P < 0. 0001], as well as significant reductions in the levels of inhibitory cytokines interleukin-10 ( 41. 40 ± 11. 89 pg/ml vs 56. 53 ± 27. 85 pg/ml, t = 2. 639, P = 0. 019) and interleukin-35 ( 122. 9 ± 9. 98 pg/ml vs 130. 0 ± 15. 98 pg/ml, t = 2. 459, P = 0. 028) and significant increases in the levels of antiviral cytokines interferon-α ( 297. 5 ± 83. 56 pg/ml vs 235. 6 ± 67. 72 pg/ml, t = 2. 603, P = 0. 017) and interferon-γ ( 5. 83 ± 0. 85 pg/ml vs 4. 39 ± 0. 95 pg/ml, t = 4. 659, P = 0. 0004) . Conclusion Thymosin α1 can inhibit the level and immunosuppressive function of CD4+CD25+CD127dim/-Treg cells in CHB patients and improve their immune function.
- hepatitis B, chronic /
- T-lymphocytes, regulatory /
- thymosin

HTML全文

参考文献(17)

[1]WU FP, DANG SS.Research advances in immune tolerance in chronic hepatitis B virus infection[J].J Clin Hepatol, 2017, 33 (5) :949-953. (in Chinese) 吴凤萍, 党双锁.慢性HBV感染免疫耐受研究进展[J].临床肝胆病杂志, 2017, 33 (5) :949-953.

[2]SASIDHARAN NAIR V, ELKORD E.Immune checkpoint inhibitors in cancer therapy:a focus on T-regulatory cells[J].Immunol Cell Biol, 2018, 96 (1) :21-33.

[3]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[4]ZHANG Y, LIAN JQ, HUANG CX, et al.Overexpression of Tolllike receptor 2/4 on monocytes modulates the activities of CD4 (+) CD25 (+) regulatory T cells in chronic hepatitis B virus infection[J].Virology, 2010, 397 (1) :34-42.

[5]LI X, TIAN L, DONG Y, et al.IL-35 inhibits HBV antigenspecific IFN-γ-producing CTLs in vitro[J].Clin Sci, 2015, 129 (5) :395-404.

[6]SHAO X, MA J, JIA S, et al.Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection[J].Front Cell Infect Microbiol, 2017, 7:472.

[7]TIAN ZF, YOU ZL, YI H, et al.Effect of entecavir on CD4+Tcell subpopulations in patients with chronic hepatitis B[J].Ann Hepatol, 2016, 15 (2) :174-182.

[8]HAO C, WANG J, KANG W, et al.Kinetics of Th17 cytokines during telbivudine therapy in patients with chronic hepatitis B[J].Viral Immunol, 2013, 26 (5) :336-342.

[9]CHEN T, ZHU L, SHI A, et al.Functional restoration of CD56 (bright) NK cells facilitates immune control via IL-15 and NKG2D in patients under antiviral treatment for chronic hepatitis B[J].Hepatol Int, 2017, 11 (5) :419-428.

[10]PAN Y, WANG LN, SONG ZX, et al.Comparison of effects of entecavir and interferon therapy for HBe Ag-positive chronic hepatitis B[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition, 2016, 10 (4) :382-395. (in Chinese) 潘玉, 王莉娜, 宋正霞, 等.恩替卡韦与干扰素治疗HBe Ag阳性慢性乙型肝炎的疗效[J/CD].中华实验和临床感染病杂志:电子版, 2016, 10 (4) :392-395.

[11]ZHANG HQ, LIU H, ZHOU T.Clinical effect of adefovir dipivoxil combined with thymosinα1 in the treatment of paitents with HBe Ag positive and no response to lamivudine[J].Int J Virol, 2016, 23 (2) :124-126. (in Chinese) 张华强, 刘海, 周涛.阿德福韦酯联合胸腺肽α1治疗拉米夫定无应答的HBe Ag阳性慢性乙肝的疗效观察[J].国际病毒学杂志, 2016, 23 (2) :124-126.

[12]HE C, PENG W, LI C, et al.Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection[J].Medicine, 2017, 96 (16) :e6606.

[13]TONG J, SUN CY, YANG LB, et al.Effect of thymosinα1 on lymphocyte subsets in patients with decompensated hepatitis B cirrhosis[J].J Clin Hepatol, 2017, 33 (11) :2132-2135. (in Chinese) 仝静, 孙长宇, 杨黎冰, 等.胸腺肽α1对乙型肝炎肝硬化失代偿期患者淋巴细胞亚群的影响[J].临床肝胆病杂志, 2017, 33 (11) :2132-2135.

[14]DING JH, WANG LL, CHEN Z, et al.The role of Tα1 on the infective patients after hematopoietic stem cell transplantation[J].Int J Hematol, 2013, 97 (2) :280-283.

[15]GARIB FY, RIZOPULU AP.T-regulatory cells as part of strategy of immune evasion by pathogens[J].Biochemistry, 2015, 80 (8) :957-971.

[16]CHEN X, DU Y, LIN X, et al.CD4+CD25+regulatory T cells in tumor immunity[J].Int Immunopharmacol, 2016, 34:244-249.

[17]LIN FC, YOUNG HA.Interferons:success in anti-viral immunotherapy[J].Cytokine Growth Factor Rev, 2014, 25 (4) :369-376.

施引文献

资源附件(0)

访问统计

本文二维码

计量

文章访问数: 2189
HTML全文浏览量: 46
PDF下载量: 392
被引次数: 0

用微信扫码二维码

分享至好友和朋友圈

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

胸腺肽α1对慢性乙型肝炎CD4+CD25+CD127dim/-调节性T淋巴细胞功能的影响

DOI: 10.3969/j.issn.1001-5256.2018.05.017

计量

Effect of thymosin α1 on the function of CD4+CD25+CD127dim/- regulatory T cells in chronic hepatitis B patients

计量

目录

留言板

胸腺肽α1对慢性乙型肝炎CD4+CD25+CD127dim/-调节性T淋巴细胞功能的影响

DOI: 10.3969/j.issn.1001-5256.2018.05.017

计量

出版历程

Effect of thymosin α1 on the function of CD4+CD25+CD127dim/- regulatory T cells in chronic hepatitis B patients

计量

出版历程

目录

关于本刊

投稿指南

在线期刊

肝胆学院

指南共识